European Medicines Agency

#Drug discovery #European Medicines Agency #European Union #Regulatory

104 new drugs approved in Europe in 2025

In 2025, the European Medicines Agency (EMA) recommended 104 medicines for marketing authorisation, 38 of which had a new active substance which had never been authorised in the European Union (EU) before.   These included the first medicine to treat non-cystic fibrosis bronchiectasis, a first-in-class treatment to delay the onset of… Read More

#News #Regulatory

AI
#Artificial intelligence (AI) #Drug discovery #European Medicines Agency #FDA

EMA and FDA set common principles for AI in drug development

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly identified 10 principles for good artificial intelligence (AI) practice in the medicines lifecycle.  The principles give broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research… Read More

#Editor's Choice #Editor's Pick #News #Regulatory

GSK offices
#CHMP #European Medicines Agency #GSK #Respiratory

CHMP supports two GSK respiratory drugs for 2026 approval

GSK has announced positive opinions from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of two new potential medicines for respiratory diseases.  Depemokimab has been recommended as add-on maintenance treatment for severe asthma with type 2 inflammation (12+) and as an add-on… Read More

#News #Regulatory

European Commission
#EU #European Commission #European Medicines Agency #Personalised medicine #Regulatory

New agreement to reshape EU pharmaceutical legislation

A landmark political agreement has been reached by the European Commission, the European Parliament and the Council of the European Union on a comprehensive reform of the EU pharmaceutical legislation. The agreement represents the most significant overhaul of the regulatory framework in over two decades and is described as a… Read More

#News #Regulatory #Trending News

Leukaemia
#Acute Myeloid Leukaemia #Biotech #European Medicines Agency

Ipsen acquires ImCheck Therapeutics for AML treatment

Pharmaceutical company Ipsen is set to purchase French biotechnology company ImCheck Therapeutics to develop acute myeloid leukaemia (AML) treatment ICT01.  ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer, which received Orphan Drug Designations from the US Food and Drug Administration and European… Read More

#Business & Investment #News

#Drug discovery #European Medicines Agency #FDA #Health Canada #Regulatory

This week in drug discovery (25-29 August) 

News round-up for 25-29 August by DDW Senior Digital Content Editor Diana Turner. There have been some significant regulatory decisions this week, including a new orphan designation from the EMA and the FDA go-ahead for Rocket Pharma’s paused gene therapy trial. The top stories:… Read More

#News

The European Medicines Agency in Amsterdam
#European Medicines Agency #Graft vs Host Disease #Orphan drugs #ReAlta

Graft-versus-host treatment gets EMA orphan drug designation

The European Medicines Agency (EMA) has granted orphan drug designation to ReAlta’s RLS-0071 (pegtarazimod) for the treatment of graft-versus-host disease (GvHD).  The Orphan Drug Designation was supported by preliminary data from ReAlta’s ongoing Phase II trial, which included data from the initial cohort of steroid-refractory acute GvHD (aGvHD) patients.   The… Read More

#News #Regulatory

Non-small cell lung cancer
#BeOne Medicines #CHMP #European Medicines Agency #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

Positive CHMP opinion for Tevimbra in neoadjuvant/adjuvant NSCLC

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Tevimbra (tislelizumab) for resectable non-small cell lung cancer (NSCLC).  It is recommended in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for adult patients at… Read More

#News #Regulatory

#European Medicines Agency #Gene therapy #Kidney disease #Orphan drugs #Purespring Therapeutics

EMA orphan designation for IgA nephropathy gene therapy

The European Medicines Agency (EMA) has granted orphan drug designation to Purespring Therapeutics’ PS-002 in IgA nephropathy (IgAN), an autoimmune kidney disease that primarily affects young adults.  Orphan drug designation in the European Union (EU) provides incentives including market exclusivity, protocol assistance (guidance on study design and scientific evaluation) and… Read More

#News #Regulatory

Biliary tract
#CHMP #European Medicines Agency #Jazz Pharmaceuticals #Oncology

CHMP issues positive opinion for biliary tract cancer treatment

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the conditional marketing authorisation of the EU’s first HER2-targeted therapy for biliary tract cancer (BTC).  Zanidatamab is an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody.  It is recommended as… Read More

#News #Regulatory

#Artificial intelligence (AI) #Clinical trial design #Clinical trials #European Medicines Agency #Liver disease

EMA qualifies first AI tool to diagnose liver disease in trials

The European Medicine Agency’s (EMA’s) human medicines committee (CHMP) has issued the first Qualification Opinion (QO) on a development methodology based on artificial intelligence (AI).   The tool, called AIM-NASH, helps pathologists analyse liver biopsy scans to identify the severity of MASH (metabolic dysfunction associated steatohepatitis; formerly known… Read More

#News

EMA
#European Medicines Agency #Monoclonal antibodies #Paediatrics #Phase III trial #Regeneron Pharmaceuticals #Sanofi

EU Dupixent use extended to children with eosinophilic esophagitis

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year old. The approval is limited to children aged one to 11 years who weigh at least 15kg and who are inadequately controlled by, intolerant to, or who are not candidates… Read More

#News #Regulatory

The European Medicines Agency in Amsterdam
#AstraZeneca #CHMP #European Medicines Agency #Rare disease

EU CHMP recommends new indication for AZ’s benralizumab

AstraZeneca’s Fasenra (benralizumab) has been recommended for approval in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. If… Read More

#News #Regulatory

Human liver
#European Medicines Agency #Liver disease #Orphan drugs #Rare disease #SeaBeLife

Orphan drug prevents cell death in acute liver failure

Biotechnology company SeaBeLife has secured orphan drug designation (ODD) from the European Medicines Agency (EMA) for its drug candidate SBL01 in the treatment of acute liver failure (ALF). ALF occurs when the liver suddenly loses its ability to function in a person without a pre-existing liver… Read More

#News

Stamp of approval
#CHMP #EMA #European Medicines Agency #European Union #Marketing approval authorisation

EU’s CHMP supports 14 new medicines, but rejects lecanemab

The European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended 14 medicines for approval at its July 2024 meeting. However, the CHMP recommended not granting a marketing authorisation for Leqembi (lecanemab) for the treatment of Alzheimer’s disease. The committee said that the observed effect of Leqembi… Read More

#News #Regulatory #Trending News

EMA concept
#Chronic obstructive pulmonary disease (COPD) #European Medicines Agency #Sanofi

Dupixent first targeted therapy for COPD approved in EU

The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils. The approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist… Read More

#News #Regulatory #Trending News